paroxetine has been researched along with clovoxamine in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Bojarski, AJ; Bugno, R; Duszyńska, B; Hogendorf, A; Hogendorf, AS; Kurczab, R; Lenda, T; Pietruś, W; Satała, G; Staroń, J; Wantuch, A; Warszycki, D | 1 |
Block, P; Fieve, RR; Peselow, ED; Robins, CJ; Sanfilipo, MP | 1 |
Difiglia, C; Fieve, RR; Peselow, ED; Sanfilipo, MP | 1 |
1 review(s) available for paroxetine and clovoxamine
Article | Year |
---|---|
Melancholic/endogenous depression and response to somatic treatment and placebo.
Topics: Antidepressive Agents; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 1992 |
2 trial(s) available for paroxetine and clovoxamine
Article | Year |
---|---|
Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Individuality; Internal-External Control; Interpersonal Relations; Male; Oximes; Paroxetine; Piperidines; Serotonin Antagonists | 1992 |
Melancholic/endogenous depression and response to somatic treatment and placebo.
Topics: Antidepressive Agents; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 1992 |
1 other study(ies) available for paroxetine and clovoxamine
Article | Year |
---|---|
Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Ligands; Models, Molecular; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2021 |